Benzinga | May 11, 2021 05:56AM EDT

Keybanc Initiates Coverage On Recursion Pharmaceuticals with Overweight Rating, Announces Price Target of $36

Keybanc analyst Donald Hooker initiates coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight rating and announces Price Target of $36.